<SEC-DOCUMENT>0001437749-20-019081.txt : 20200901
<SEC-HEADER>0001437749-20-019081.hdr.sgml : 20200901
<ACCEPTANCE-DATETIME>20200901092749
ACCESSION NUMBER:		0001437749-20-019081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200827
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200901
DATE AS OF CHANGE:		20200901

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC.
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		201153427

	BUSINESS ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		(973) 535-2717

	MAIL ADDRESS:	
		STREET 1:		220 SOUTH ORANGE AVENUE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MILESTONE SCIENTIFIC INC/NJ
		DATE OF NAME CHANGE:	19970409

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mlss20200831_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head>
	<title>mlss20200831_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 9/1/2020 2:10:08 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>U</b><b>NITED STATES </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt;text-align:center;"><b>SECURITIES AND EXCHANGE COMMISSION</b>&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;"><b>FORM 8-K</b>&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:18pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CURRENT REPORT<br>
Pursuant to Section&nbsp;13 </b><b>o</b><b>r 15(d) of </b><b>t</b><b>he Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Date of Report (Date of earliest event reported): </b><b>August 27</b><b>, 20</b><b>20</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:24pt;margin:0pt;text-align:center;"><b>Milestone</b><b> </b><b>Scientific</b><b> Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Exact name of registrant as specified in its charter)</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Delaware</b><br>
			(State or other jurisdiction<br>
			of incorporation)</p>
			</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>00</b><b>1</b><b>-</b><b>14053</b><br>
			(Commission<br>
			File Number)</p>
			</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>13-3545623</b><br>
			(IRS Employer<br>
			Identification No.)</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>425 Eagle Rock Avenue</b><b>&nbsp;</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Suite 403</b><b>&nbsp;</b><br>
			<b>Roseland</b><b>, New Jersey</b><br>
			(Address of principal executive offices)</p>
			</td>
			<td style="vertical-align:bottom;width:5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:47.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>070</b><b>68</b><br>
			(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Registrant&#8217;s telephone number, including area code <b>(</b><b>973) 535-2717</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Former name or former address, if changed since last report.)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; border-color: black black rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 33.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Title of each class</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 28%; border-top: 1px solid black;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Trading Symbol(s)</p>
			</td>
			<td style="vertical-align: top; border-color: black black rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 39.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Name on exchange on which registered</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 33.6%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Common Stock</p>
			</td>
			<td style="vertical-align:top;border-bottom:solid 1px #000000;;width:28%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">MLSS</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 39.5%; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">NYSE American</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#9744; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-top:0pt;text-align:left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 30.95pt;text-align:center;">Emerging growth company &#9744;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:30.6pt;margin-right:0pt;margin-top:0pt;text-align:left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:30.6pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>Item 5.02 &#8212; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">On August 27, 2020, Brent Johnston resigned as President of Milestone Scientific Inc. (the &#8220;Company&#8221;), effective September 8, 2020.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">On September 1, 2020, the Company announced the appointment of Jan Adriaan (Arjan) Haverhals as President of the Company, effective September 8, 2020. Mr. Haverhals, is currently the President and Chief Executive Officer of the Company&#8217;s wholly-owned subsidiary Wand Dental Inc. and will continue in that position.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">Mr. Haverhals joined the Company in June 2020 and brings over 30 years of experience in sales, marketing, product development, and international expansion within the medical device, pharmaceutical, and other industries. Prior to joining the Company, Mr. Haverhals was senior vice president of sales at Xcentric Mold &amp; Engineering, where he was instrumental in increasing sales productivity and efficiency for the company's prototype injection molding services, which included leading healthcare company clients. Previously, at Straumann, LLC, a global leader in manufacturing medical and dental devices, he held a series of senior sales and marketing roles including vice president of customer marketing &amp; education, where he oversaw all product franchises and led the launch of more than 30 products in the North American market. He also served as senior vice president for the Nordic Region at Straumann AB, senior vice president of global sales digital solutions, which included oversight of the strategic acquisition of Etkon; and served as vice president of the Prosthetics Business Unit, where he introduced a new implant and prosthetics product line within a new market segment. He also served as vice president of global marketing &amp; sales at Elkem AS, one of Norway's largest industrial companies. Previously, Mr. Haverhals served as executive vice president of marketing &amp; sales at Cresco Ti Systems S&#224;rl, a global dental implant company, where he was responsible for turning around and managing global sales, marketing, international business. Mr. Haverhals holds an MS in Pharmacy from the University of Leyden in the Netherlands.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>Item </b><b>8</b><b>.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b><b>Other Events</b><b> </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">On September 1, 2020, the Company issued a press release announcing that the appointment of Mr. Haverhals as President. The press release is attached hereto as Exhibit 99.1.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 80%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; margin-right: auto;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><b>(d)</b></p>
			</td>
			<td style="vertical-align: top; width: 74%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Exhibits</b></p>
			</td>
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following exhibit is filed with this report:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin-left: 27pt; width: 80%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 12%; border-left: 1px solid black; border-top: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">99.1</p>
			</td>
			<td style="vertical-align: top; border-color: black black rgb(0, 0, 0); border-style: solid; border-width: 1px; width: 88%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left; text-indent: 0pt;"><a href="ex_202332.htm" style="-sec-extract:exhibit;">Press Release, dated September 1, 2020&nbsp;</a></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>SIGNATURES </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:0.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:33.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="3" style="vertical-align:middle;width:39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><b>Milestone Scientific</b><b> Inc.<br>
			&nbsp;</b></p>
			</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dated: September 1, 2020&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:&nbsp;&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;border-bottom:solid 1px #000000;;width:34%;">/s/ Joseph D&#8217;Agostino&nbsp;</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align:middle;width:34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Joseph D&#8217;Agostino&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:47%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:4.9%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align:middle;width:14%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td colspan="5" style="vertical-align:middle;width:100%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_202332.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_202332.htm</title>

	<!-- Generated by ThunderDome Portal - 8/31/2020 10:17:15 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><img src="ex_202332img001.jpg" style="width: 196pt; height: 70pt;"></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Contact:</b><br>
David Waldman or Natalya Rudman<br>
Crescendo Communications, LLC<br>
Email: <u>mlss@crescendo-ir.com</u><br>
Tel: 212-671-1020</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Milestone Scientific </b><b>Promotes</b><b> </b><b>Arjan Haverhals </b><br>
<b>to</b><b> President </b><b>of Milestone Scientific</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>ROSELAND</b><b>, NJ, </b><b>September 1, 2020</b><b> &#8211; Milestone Scientific Inc. (NYSE: MLSS)</b>, a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has promoted Jan Adriaan (Arjan) Haverhals to President of Milestone Scientific, replacing Brent Johnston. Mr. Haverhals will continue to serve as President and Chief Executive Officer of the Company&#8217;s Wand Dental, Inc. subsidiary.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Mr. Haverhals joined Milestone in June 2020 and brings over 30 years of experience in sales, marketing, product development, and international expansion within the medical device, pharmaceutical, and other industries. Mr. Haverhals has been responsible for the growth and profitability of both startups and global industry leaders, organically and through strategic acquisitions. Since Mr. Haverhals&#8217; recent appointment as President and CEO of Wand Dental, he has enhanced the sales and marketing initiatives around the dental instrument and introduced new collaboration and distribution opportunities. Additionally, as President of Milestone, Mr. Haverhals will take a more active role in accelerating the commercialization of Milestone&#8217;s CompuFlo&#174; Epidural Instrument and CathCheck&#8482;, both in the U.S. and in Europe, as well as oversee regulatory activities and product manufacturing.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Leonard Osser, Interim CEO of Milestone Scientific, stated, "I am very pleased to announce Arjan&#8217;s promotion to President of Milestone Scientific. In the short time since he joined the organization, he has demonstrated strong leadership, organizational skills and sales acumen. His contributions are already evident in the enhanced sales and marketing activities around the dental instrument. In terms of the CompuFlo&#174; Epidural Instrument and CathCheck&#8482;, we look forward to his active involvement as we advance discussions with major hospitals and health systems across the U.S. We are also benefitting from his extensive relationships across Europe. We believe Arjan will play a central role in terms of accelerating the commercialization of CompuFlo&#174; and CathCheck&#8482;, as we work towards our goal of establishing the instrument as standard of care around the world. Additionally, we would like to thank Brent Johnston, former President of Milestone, for his contributions to the Company and wish him well in his future endeavors.&#8221;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Prior to joining the Company, Mr. Haverhals was senior vice president of sales at Xcentric Mold &amp; Engineering, where he was instrumental in increasing sales productivity and efficiency for the company's prototype injection molding services, which included leading healthcare company clients. Previously, at Straumann, LLC, a global leader in manufacturing medical and dental devices with over $1 billion in sales, he held a series of senior sales and marketing roles including vice president of customer marketing &amp; education, where he oversaw all product franchises and led the launch of more than 30 products in the North American market, resulting in double-digit growth. He also served as senior vice president for the Nordic Region at Straumann AB, senior vice president of global sales digital solutions, which included oversight of the strategic acquisition of Etkon; and served as vice president of the Prosthetics Business Unit, where he introduced a new implant and prosthetics product line within a new market segment. He also served as vice president of global marketing &amp; sales at Elkem AS, one of Norway's largest industrial companies. Previously, Mr. Haverhals served as executive vice president of marketing &amp; sales at Cresco Ti Systems S&#224;rl, a global dental implant company, where he was responsible for turning around and managing global sales, marketing, international business, where he achieved over 100% return on investment for shareholders. Mr. Haverhals holds an MS in Pharmacy from the University of Leyden in the Netherlands.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>About Milestone Scientific Inc.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone&#8217;s proprietary DPS Dynamic Pressure Sensing technology&#174; is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: <u>www.milestonescientific.com</u>.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Safe Harbor Statement</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>&nbsp;</b></i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><i>&nbsp;</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i># # #</i></p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex_202332img001.jpg
<TEXT>
begin 644 ex_202332img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" !> 08# 2(  A$! Q$!_\0
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ME]X6TS49O,N4WGWH52T^>P<MU8\K\-?&+PMH7@VSMKBTUB:YBA16CBTV7J%
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MIUH3L,Y/P7X@M_$FLZIJ=E)*ID6&.6WF)W6\BA@R%3]U@>OKP:R/$%K)I_Q
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)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
